Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 19;12(9):1536.
doi: 10.3390/jpm12091536.

Effects of Oral Supplementation with Myo-Inositol and D-Chiro-Inositol on Ovarian Functions in Female Long-Term Survivors of Lymphoma: Results from a Prospective Case-Control Analysis

Miriam Dellino  1   2 , Eliano Cascardi  3   4 , Claudia Leoni  5 , Francesca Fortunato  6 , Annarita Fusco  7 , Raffaele Tinelli  8 , Gerardo Cazzato  9 , Salvatore Scacco  10 , Antonio Gnoni  10 , Antonio Scilimati  11 , Vera Loizzi  12 , Antonio Malvasi  1 , Anna Sapino  3   4 , Vincenzo Pinto  1 , Ettore Cicinelli  1 , Giovanni Di Vagno  2 , Gennaro Cormio  13 , Vito Chiantera  14 , Antonio Simone Laganà  14
Affiliations

Effects of Oral Supplementation with Myo-Inositol and D-Chiro-Inositol on Ovarian Functions in Female Long-Term Survivors of Lymphoma: Results from a Prospective Case-Control Analysis

Miriam Dellino et al. J Pers Med. .

Abstract

The progressive improvement of lymphoma treatment has led to an important prolongation of patient survival and life expectancy. The principal international scientific societies of oncology now therefore recommend that long-term survivors of lymphoma join fertility programs. Specifically, fertile-age patients should be assisted by a multidisciplinary team, including specialists dedicated to fertility preservation in oncology, in order to support the completion of their reproductive project. In the general population, the use of Myo-Inositol and D-Chiro-Inositol (MI/DCI) has been demonstrated to be an effective choice to treat ovarian dysfunctions, with a consequent improvement in reproductive outcomes, so it may represent an adjuvant strategy for this purpose. We therefore conducted a pilot prospective case-control study to evaluate the potentialities of this nutritional supplement, with the aim of optimizing reproductive function in female long-term survivors of lymphoma. One group underwent oral supplementation with MI 1200 mg and DCI 135 mg per day for 12 months, compared with controls who underwent no treatment in the same period. After 12 months, FSH, LH, and progesterone levels, as well as oligomenorrhea and antral follicle count (AFC), were significantly improved in the MI/DCI group. In addition, a significantly higher mean value in FSH and LH and a significantly lower mean AFC value in the right ovary were observed in controls compared to the MI/DCI group. Despite the need for further investigation, MI/DCI could be considered a potential adjuvant strategy to restore ovarian function in female long-term survivors of lymphoma.

Keywords: Inositol; fertility preservation; health promotion; lymphoma; precision medicine; reproductive outcomes.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow-chart for inclusion and treatment of long-term survivors of lymphoma. MI/DCI: Myo-Inositol and D-Chiro-Inositol oral supplementation.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Barr R.D. Risk of premature menopause after treatment for Hodgkin’s lymphoma. J. Natl. Cancer Inst. 2014;106 doi: 10.1093/jnci/dju231. - DOI - PubMed
    1. Behringer K., Thielen I., Mueller H., Goergen H., Eibl A.D., Rosenbrock J., Halbsguth T., Eichenauer D.A., Fuchs M., Reiners K.S., et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Ann. Oncol. 2012;23:1818–1825. doi: 10.1093/annonc/mdr575. - DOI - PubMed
    1. Engert A., Diehl V., Franklin J., Lohri A., Dörken B., Ludwig W.-D., Koch P., Hänel M., Pfreundschuh M., Wilhelm M. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J. Clin. Oncol. 2009;27:4548–4554. doi: 10.1200/JCO.2008.19.8820. - DOI - PubMed
    1. Swerdlow S., Campo E., Pileri E., Harris N., Stein H., Siebert R. The updated who classification of hematological malignancies. The 2016 revision of the WHO classification of lymphoid neoplasms. Blood. 2016;127:2375–2390. doi: 10.1182/blood-2016-01-643569. - DOI - PMC - PubMed
    1. Traila A., Dima D., Achimas-Cadariu P., Micu R. Fertility preservation in Hodgkin’s lymphoma patients that undergo targeted molecular therapies: An important step forward from the chemotherapy era. Cancer Manag. Res. 2018;10:1517–1526. doi: 10.2147/CMAR.S154819. - DOI - PMC - PubMed

LinkOut - more resources